$16 Million and Counting: The First Instance Lexapro Judgment That Sparked Australia's Biggest Pharma Patent Appeal

$16 Million and Counting: The First Instance Lexapro Judgment That Sparked Australia's Biggest Pharma Patent Appeal

In November 2018, Justice Jagot of the Federal Court of Australia handed down one of the most closely watched pharmaceutical patent decisions in recent Australian history. H Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797 awarded Lundbeck over AUD $16 million in patent infringement damages relating to the antidepressant escitalopram (Lexapro). The decision was later overturned on appeal — but understanding the reasoning at first instance is essential for any business operating in the pharmaceutical, generic drug, or patent licensing space.

The Setting: Escitalopram and Australia's Patent Term Extension Regime

Escitalopram, the active ingredient in Lexapro, is an SSRI antidepressant that became a blockbuster pharmaceutical product globally. H Lundbeck A/S, the Danish originator company, held Australian patent protection for escitalopram. Under Australia's Patents Act 1990 (Cth), pharmaceutical patent holders can apply for a patent term extension (PTE) of up to five years to compensate for time lost in regulatory approval processes before a drug can reach market.

The standard 20-year patent term for Lundbeck's escitalopram patent expired in June 2009. Lundbeck had obtained a PTE in 2004, but that extension was subsequently held invalid in separate proceedings — a significant blow to an innovator pharmaceutical company that had invested heavily in developing the drug. Through years of complex litigation, Lundbeck ultimately succeeded in obtaining a new, valid five-year extension in June 2014, backdated to cover the period from June 2009 through to December 2012.

This tortuous history created a legal peculiarity: the patent was now, retroactively, enforceable during a period when Sandoz — a generic pharmaceutical manufacturer — had already launched and been selling generic escitalopram, believing the original patent had expired.

The 2007 Settlement Agreement: A Critical Document

Before the original patent expired, Lundbeck and Sandoz were embroiled in patent litigation. In 2007, they settled. The settlement deed gave Sandoz what was called an "early-entry licence" to sell generic escitalopram commencing two weeks before the anticipated June 2009 expiry of the original patent.

Sandoz proceeded to launch its generic product in June 2009, on the strength of that licence. At the time, the original patent had expired and the failed PTE was water under the bridge. No one in 2007 could have anticipated that Lundbeck would, seven years later, secure a fresh valid extension retroactively covering the same period.

Justice Jagot's Findings: Licence Ceased on Original Expiry

The central question before Justice Jagot was whether the early-entry licence granted by the 2007 settlement deed continued to protect Sandoz's generic sales during the extended patent term (June 2009–December 2012).

Her Honour found that it did not. On construction of the settlement agreement, the early-entry licence commenced in May 2009 (two weeks before original expiry) and ceased to operate when the original patent expired in June 2009. Justice Jagot reasoned that in 2007, when the settlement was struck, the parties were not contemplating a later-granted patent term extension. The licence was tied to the life of the original patent. Once that original patent expired, the licence expired with it. It could not, in her Honour's view, spontaneously revive or extend to cover a new extended term created by litigation that concluded years later.

That reasoning had an inevitable consequence: Sandoz had no licence covering its generic escitalopram sales from June 2009 onwards (during the extended term), and those sales therefore constituted patent infringement.

Damages: Over AUD $16 Million

Lundbeck was awarded damages exceeding AUD $16 million for Sandoz's infringing sales during the extended term. This figure reflected the commercial significance of the escitalopram market in Australia and the lengthy period of the extended term during which the infringement was found to have occurred.

The decision also considered claims of misleading and deceptive conduct under the Australian Consumer Law, arising from representations made by Sandoz about its entitlement to sell generic escitalopram. These claims added further dimensions to an already complex proceeding.

Why the Decision Was Appealed — and Overturned

Sandoz appealed. The Full Federal Court in Sandoz Pty Ltd v H Lundbeck A/S [2020] FCAFC 133 reversed Justice Jagot's decision. The Full Court held that, applying objective commercial construction principles, a reasonable businessperson would have understood the early-entry licence to continue operating during any extended patent term — not to terminate at original expiry in circumstances that would immediately expose Sandoz to infringement liability for sales it had just been licensed to make.

The Full Court's reversal does not diminish the significance of the first instance judgment, which set out a detailed and careful analysis of the construction question and the underlying patent law issues. The divergence between the two decisions illustrates how genuinely difficult commercial construction questions can be, particularly in the context of complex pharmaceutical patent litigation.

Key Legal Issues This Case Illuminates

Patent Term Extensions and Strategic Risk

Australia's PTE regime can produce unexpected retroactive effects. A company that believes a patent has expired may find itself liable for infringement if the patentee subsequently obtains a valid extension covering the same period. This risk is particularly acute in the pharmaceutical sector, where PTE litigation is common and protracted.

Construction of IP Settlement Agreements

Settlement agreements resolving patent disputes are commercial contracts. Their meaning is determined by what reasonable businesspeople in the parties' positions would have understood — but as this case shows, courts can reach different conclusions on that question. Ambiguity is expensive.

Misleading and Deceptive Conduct in Patent Disputes

Representations about the scope of patent rights — including whether a party is or is not licensed — can give rise to claims under the Australian Consumer Law. Patent litigants need to be careful about what they say, publicly and in correspondence, about their legal position.

Practical Takeaways

• Never assume a patent has definitively expired. In the pharmaceutical sector, PTEs can be granted years after the original term ends, with retroactive effect. Generic manufacturers entering the market on expiry of an original term should monitor ongoing PTE proceedings.

• Settlement deeds must address contingencies. The 2007 settlement agreement did not expressly address what would happen if a valid PTE were later granted. That silence generated years of further litigation. Settlement deeds should expressly deal with the possibility of subsequent patent variations.

• Litigation risk must be priced into commercial decisions. Sandoz faced a $16 million damages award at first instance — a risk that would need to be assessed and provisioned for in any rational commercial planning around generic drug launches.

• Specialist pharmaceutical patent advice is essential. The interaction between standard patent rights, PTEs, settlement agreements, and infringement exposure is uniquely complex. Early, expert advice can prevent enormously costly outcomes.

Conclusion

H Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797 is a case study in the compounding complexity of pharmaceutical patent litigation in Australia. A settlement struck in good faith in 2007 became the centre of a $16 million dispute more than a decade later — because of retroactive patent extension, detailed construction analysis, and the limits of what even sophisticated parties can anticipate when resolving litigation.

For pharmaceutical companies, generic manufacturers, and any business involved in complex IP licensing, the case is essential reading. Its appeal — and the Full Court's reversal — make it even richer as a lesson in how reasonable businesspeople can see the same words differently.

Do you have questions about pharmaceutical patents, patent term extensions, or IP settlement agreements in Australia? Contact Stellar IP Law for experienced, practical guidance.